In this video, Motley Fool health-care analyst David Williamson discusses the specifics of the deals, what Sanofi is gaining, why the market loves Alnylam, and why 2015, with half a dozen proof-of-concept trials reporting, will be a big year for the stock.
You're reading a free article with opinions that may differ from The Motley Fool's Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More
Alnylam Pharmaceuticals, Inc.: Big Pharma Loves This Stock
Sanofi takes a 12% position in Alnylam.
David Williamson owns shares of Merck. Follow David on Twitter: @MotleyDavid.
The Motley Fool recommends Alnylam Pharmaceuticals. We Fools don't all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.
Stocks Mentioned



*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.
Related Articles





Premium Investing Services
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.